1.
66例非小细胞肺癌患者的一般特征
Characteristics of 66 non-small cell lung cancer (NSCLC) patients
| Tatal | Gefitinib | Erlotinib | P | |
| Patients | 66 (100%) | 49 (74.2%) | 17 (25.8%) | |
| Age (yr) | 62 (39-80) | 61 (39-80) | 64 (42-78) | 0.313 |
| Gender | 0.087 | |||
| Male | 37 (56.1%) | 24 (64.9%) | 13 (35.1%) | |
| Female | 29 (43.9%) | 25 (86.2%) | 4 (13.8%) | |
| ECOG PS status | ||||
| 0-1 | 66 (100%) | 49 (74.2%) | 17 (25.8%) | |
| Smoking status | 0.249 | |||
| Former and current | 23 (34.8%) | 15 (65.2%) | 8 (34.8%) | |
| Never | 43 (65.2%) | 34 (79.1%) | 9 (20.9%) | |
| Pathological types | 0.247 | |||
| Adenocarcinoma | 58 (87.9%) | 42 (72.4%) | 16 (27.6%) | |
| Adenosquamous carcinoma | 6 (9.1%) | 6 (100%) | 0 (0) | |
| Squamous carcinoma | 2 (3.0%) | 1 (50%) | 1 (50%) | |
| Clinical stages | 0.565 | |||
| Ⅲb | 4 (6.1%) | 4 (100%) | 0 (0) | |
| Ⅳ | 62 (93.9%) | 45 (72.6%) | 17 (27.4%) | |
| Mutation type | 0.167 | |||
| 19-del (E746) | 29 (43.9%) | 24 (82.8%) | 5 (17.2%) | |
| 21-L858R | 36 (54.5%) | 24 (66.7%) | 12 (33.3%) | |
| Unknown | 1 (1.6%) | 1 (100%) | 0 (0) | |
| Treatment lines | 0.160 | |||
| 1st | 23 (34.8%) | 14 (68.9%) | 9 (31.1%) | |
| 2nd | 40(60.6%) | 33 (82.5%) | 7 (17.5%) | |
| 3rd and more | 3 (4.6%) | 2 (66.7%) | 1 (33.3%) |